Summary Although cytotoxic chemotherapy is widely used in advanced breast cancer, there are no powerful predictors for the therapy response. Because topoisomerase Ila (Topo Ila) is the molecular target for the anthracycline class of anti-cancer drugs, we compared the immunocytochemical assay of Topo Ila with other biomarkers in the prediction of clinical response to Topo II inhibitor chemotherapy. Fifty-five patients with advanced breast cancer were treated with a single cytotoxic drug, Topo Il-inhibitor, epirubicin (30 mg m-2 weekly up to 1000 mg m-2), as first line cytotoxic chemotherapy. Objective response to treatment was analysed according to UICC criteria. The predictive value of Topo Ila expression, c-erbB2 oncoprotein, p53 tumour-suppressor protein, oestrogen (ER) and progesterone receptor (PR), S-phase fraction and DNA ploidy were analysed from representative formalin-fixed paraffin-embedded primary tumour samples. The proportion of Topo Ila-positive cells (Topo Ila index) failed to predict response to epirubicin therapy. Mean Topo Ila scores in 29 responding patients were similar when compared with those with no change in disease progression (n = 13) and those with progressive disease (n = 13) (14.9% ± 11.4% vs 15.5% ± 7.6% vs 17.3% ± 13.2%, not significant). Among the other biomarkers tested, overexpression of c-erbB2 oncoprotein and hormone receptor negativity were significantly associated with poor response. Response rate in patients with c-erbB2-overexpressing tumours was 32% compared with 65% in patients with no c-erbB2 overexpression (P = 0.0058). Accordingly, the response rate for ER-positive patients was 67% compared with 26% in ER-negative patients (P = 0.0021). Although both negative ER status and c-erbB2 overexpression are associated with high Topo Ila expression in breast cancer, step-wise logistic regression analysis showed that ER and c-erbB2 were associated with therapy response independent of Topo Ila expression. Histological grade, p53, DNA-ploidy, tumour proliferation rate (S-phase fraction), stage of the disease at diagnosis, age of the patient, previous anti-oestrogen therapy or site of metastasis did not predict the response to epirubicin therapy. In conclusion, despite extensive in vitro evidence, expression of Topo Ila is unlikely to predict the response to Topo II inhibitor chemotherapy in advanced breast cancer. Among the prognostic biomarkers, overexpression of c-erbB2 oncogene and negative ER may have predictive value in epirubicin therapy in patients with advanced breast cancer.
Patients with advanced breast cancer are commonly treated with cytotoxic chemotherapy. Whereas response to endocrine therapy can be effectively predicted by hormone receptor status, prediction of response to cytotoxic chemotherapy currently lacks reliable predictive markers (Clark, 1996) . Such factors would be of utmost use, not only in the prediction of response to chemotherapy in general but also in aiding selection between different types of cytotoxic chemotherapy. With increasing number of effective chemotherapeutic agents, selection between different regimens for individual patients according to the predictive factors might improve the efficiency of chemotherapy.
Chemotherapy with anthracyclines (doxorubicin and its derivatives, such as epirubicin) is well established in advanced breast cancer. The mechanism of action of these compounds is related to the inhibition of topoisomerase II (Topo II) enzyme. Topo II is a eukaryotic homodimeric enzyme that exists in two isoforms in human cells: the 170-kDa form (Topo Ila) and the 180-kDa form (Topo I1j) . Whereas Topo Ila is a key enzyme in DNA metabolism, having key roles in DNA replication and chromosome partitioning during cell division, the function of Topo 111 is poorly defined (Chen and Liu, 1994; Watt and Hickson, 1994; FroelichAmmon and Osheroff, 1995; Wang, 1996) . Drugs targeted against Topo II interfere with its DNA cleavage-rejoining action, trapping Topo IIa enzyme with DNA in a non-cleavable complex (Chen and Liu, 1994; Watt and Hickson, 1994; Froelich-Ammon and Osheroff, 1995) . This results in the accumulation of stabilized double-stranded DNA breaks, which are lethal to the cell at the G2M-phase of the cell cycle (Froelich-Ammon and Osheroff, 1995; Nitiss and Beck, 1996) .
In vitro studies using different experimental designs have shown that sensitivity to Topo II-inhibiting drugs is dependent on the expression level of Topo IIa gene in target cancer cells (Davies et al, 1988; Fry et al, 1991; Gudkov et al, 1993; Asano et al, 1996a,b; Vassetzky et al, 1996; Withoff et al, 1996a,b) . Cells with a low concentration of Topo Ilo protein form fewer Topo I-mediated DNA strand breaks and are less sensitive to Topo II-inhibiting drugs than cells containing a high concentration of Topo llac (Davies et al, 1988; Fry et al, 1991; Gudkov et al, 1993; Asano et al, 1996a,b; Vassetzky et al, 1996; Withoff et al, 1996b) . These in vitro findings suggest testing whether assays of Topo IIoc protein expression could be used in a clinical setting to predict a patient's response to Topo II inhibitor chemotherapy. To date, no such clinical studies reporting the relationship between Topo Iloc expression and chemosensitivity have been published using solid tumours, although studies on the variability of Topo 11o expression in breast tumours have been published (Tuccari et al, 1993; Hellemans et al, 1995; Boege et al, 1996; Jarvinen et al, 1996; Sandri et al, 1996) . In general, high Topo IIc expression is associated with high cellular proliferation and poor histological differentiation of the tumour (Tuccari et al, 1994; Hellemans et al, 1995; Boege et al, 1996; Jarvinen et al, 1996; Sandri et al, 1996) . In addition, our recent study on a large number of breast carcinomas indicated that Topo 11z expression also correlates with negative hormone receptor content, aneuploidy and c-erbB2 overexpression (Jarvinen et al, 1996) . These all are features that are generally considered to be related with altered sensitivity to chemotherapeutic agents.
In the present study, we compared the value of Topo Iloh with other biomarkers (c-erbB2, p53, ER, PR, S-phase fraction, DNA ploidy) in the prediction of response to first-line Topo II inhibitor chemotherapy in 55 patients with advanced breast cancer.
MATERIALS AND METHODS Patients and tumours
Included in this study were 55 patients with advanced breast cancer treated with a single-agent chemotherapy programme comprising Topo II inhibitor, epirubicin (30 mg m-2 weekly up to 1000 mg m-2, for at least 3 months or until the disease progressed) between 1989 and 1995 in Tampere University Hospital. All patients received the therapy according to the schedule (no cessation of therapy due to side-effects). Epirubicin was the first-line cytotoxic chemotherapy for all patients, but 36 patients had received hormonal therapy (tamoxifen 20-40 mg day-') before epirubicin. Primary breast cancers of these patients were diagnosed and operated between 1981 and 1994, and the disease-free interval varied from I to 12.5 years. Twenty-five patients were primarily node negative (T 1-3NOMO), 28 were node positive (TI-4N1MO), and in two patients the disease was advanced when diagnosis was made (T3NlM1). All patients were followed up every 3 weeks by clinical examination and laboratory tests (haemoglobin, platelets, alanine aminotransferase, alkaline phosphatase). Further diagnostic tests (bone scan, chest radiograph, liver ultrasound and serum tumour marker CA-15-3) were performed every 3 months to aid in determining the response to treatment. The response to chemotherapy was classified into four categories: 'complete response,' CR; 'partial response,' PR; 'no change in disease progression,' NC; and 'progressive disease,' PD according to UICC criteria (Hayward et al, 1977) . The investigation was approved by the ethics committee of Tampere University Hospital and informed consent was obtained from each subject before enrolment to the study.
Specimen preparation
Routinely formalin-fixed, paraffin-embedded blocks from the primary tumour lesions were obtained from the institutes in which the patients were operated. All histopathological diagnoses were re-evaluated and histopathological grading was performed according to the Bloom and Richardson system (Bloom and 
Immunohistochemistry
Immunohistochemistry for Topo Ila was performed using a rabbit polyclonal Topo Icl antibody (Topo IIo, diluted 1:1000 from manusfacturer's stock, TopoGEN, Columbus, OH, USA) (Jarvinen et al, 1996) . Tissue sections were cut on adhesivetreated, poly-L-lysine-coated slides and dried in an oven, 37°C, overnight and 3 h in an oven at 60°C. Dewaxed sections were immersed in 10 mm EDTA (pH 8.0) at 80°C and incubated at 120°C (pressure 1.05 bar) for 10 min in an ordinary autoclave for antigen retrieval (Morgan et al, 1994; Kuukasjarvi et al, 1996) . Slides were washed at room temperature and incubated overnight at 4°C with the primary antibody. A standard avidin-biotin-peroxidase complex (ABC) technique (Vectastain Elite, Vector Laboratories, Burlingame, CA, USA) was used for visualization with diaminobenzidine as a chromogen. The diaminobenzidine reaction was intensified with the methenamine silver method as described elsewhere (Peacock et al, 1991) . Sections were counterstained with haematoxylin and mounted. Immunostaining was evaluated light microscopically using an 20x objective, by a person unaware of clinical data. The Topo IIo index was assessed by counting the percentage of Topo 1Ixo-positive cells from 400 to 1000 (average 600) carcinoma cells from a morphologically wellpreserved area. The immunohistochemistry for c-erbB2, p53 and hormone receptors was performed on adjacent tissue sections as described previously (Kallioniemi et al, 1991a; Isola et al, 1992; Kuukasjarvi et al, 1996) . Briefly, the immunohistochemistry of cerbB2, p53 and hormone receptors was carried out essentially as described above for Topo Iloc. Only intense membranous immunostaining present in a majority of cells was taken to represent overexpression of the c-erbB2 protein. ER, PR and p53-immunostaining in more than 20% of the tumour cells was regarded as immunopositivity (Kallioniemi et al, 1991; Isola et al, 1992; Kuukasjarvi et al, 1996) .
British Journal of Cancer (1998) 77 (12), [2267] [2268] [2269] [2270] [2271] [2272] [2273] Topoisomerase l/a and chemotherapy for advanced breast cancer 2269 Our immunohistochemical determination of Topo IIa on frozen sections has been previously validated using Western blotting, dual-colour immunofluorescence and mRNA in situ hybridization (Jdrvinen et al, 1996) . Now, the applicability of this assay was extended to formalin-fixed paraffin-embedded tissue sections by comparing Topo IIox expression from the randomly selected, separate set of 20 breast tumours from which both frozen and formalinfixed, paraffin-embedded tissue sections were available.
Because only primary tumours were available from epirubicintreated patients, we studied the correlation of Topo IIa expression in the primary and metastatic tumours in a separate set of eight pairs of primary and metastatic breast carcinomas (Kuukasjarvi et al, 1996) . Immunohistochemical controls for the ER, PR, p53 and c-erbB2 immunostainings have been established previously (Kallioniemi et al, 1991a; Isola et al, 1992; Kuukasjarvi et al, 1996) . the starting material, using protocols described previously (Kallioniemi, 1988 (program IL) . The association between chemosensitivity with prognostic factors was performed using 2 x 3 frequency tables (using chi-square test for linear trend) (program 4F). The independent predictive value of each marker was tested using step-wise logistic regression analysis (program LR). The association of chemosensitivity with Topo IIo score and S-phase fraction was also performed using one-way analysis of variance (ANOVA with the Welch correction for unequal variances) (program 7D).
RESULTS
Among the 55 patients treated with epirubicin, there were two CRs (4%), 27 PRs (49%), ten patients with NC (18%) and 16 patients with PD (29%). For all further analyses the two complete responders were combined together with the patients with partial response (CR and PR, n = 29). The follow-up of patients showed that survival after administration of epirubicin was significantly better in the favourably responding group (CR and PR) than in patients with NC or with PD (P < 0.0016, Figure 1 ). Treatment
British Journal of Cancer (1998) 77(12), 2267-2273 Table 2 Step-wise logistic regression analysis of independent predictive factors of response to epirubicin chemotherapy in 55 patients with advanced breast cancer before epirubicin therapy did not affect the results because epirubicin was used as the first-line chemotherapy (no prior cytotoxic drugs). Previous anti-oestrogen therapy (in 36 patients) was not associated with response to epirubicin (P = 0.20).
The association between response to epirubicin and various clinicopathological factors was examined as shown in Table 1 . None of the clinicopathological variables (age of patient, size of primary tumour, axillary lymph node status, site of metastasis in advanced disease and histological grade) was associated with response (P > 0.05 for all variables). Among the biomarkers studied, c-erbB2 oncoprotein overexpression (P = 0.0058), negative ER (P = 0.0021) and PR status (P = 0.041) were statistically significantly associated with the lack of response to chemotherapy (Table 1) . p53 tumour-suppressor protein accumulation, DNA ploidy or tumour proliferation rate (S-phase fraction) were not associated with clinical response to chemotherapy (Table 1) . A step-wise logistic regression analysis was used to demonstrate that the predictive value of ER and c-erB2 were independent of the Topo 11c score and other clinical and biological variables studied ( Table 2 ). The tumour proliferation rate (S-phase fraction) was also analysed as a continuous variable (Table 3) . Mean S-phase fractions in responders and non-responders were similar (11.0% ± 7.2% for CR and PR vs 11.6% ± 9.2% for NC vs 11.5% ± 6.3% for PD, not significant, Table 3 ).
The relationship between response to epirubicin and Topo llcc expression was the main interest in this study and was studied in detail. First, we validated our immunohistochemical Topo llIa assay for formalin-fixed, paraffin-embedded sections by comparing them with those from adjacent frozen sections used previously (Jarvinen et al, 1996) . Topo Ila scores that showed excellent correlation were found between these two sample types (correlation coefficient, r = 0.89, n = 20, Figure 2) . Next, we confirmed that Topo Ila expression measured in a primary tumour sample reflects the Topo Ila status of metastasis, which is the target of chemotherapy but from which biopsies were not available. We analysed eight pairs of primary tumour and asynchronous (Kuukasjarvi et al, 1996) and found a good correlation (r = 0.89), indicating stability of Topo Ioc expression during disease progression.
To analyse Topo IIa as a predictive factor, we first analysed it as a continuous variable in the different therapy outcome groups ( Figures  3 and 4) . The mean Topo IIa indexes were similar in tumours that responded and in tumours with no clinically relevant response (14.9% ± 11.4% for CR and PR vs 15.5% ± 7.6% for NC vs 17.3% ± 13.2% for PD, not significant, Figures 3 and 4, Table 3 ). Figure 4 also illustrates that it was not possible to define any threshold values for Topo IIa expression that could define subgroups that were associated with response or lack of response. Because Topo IlI expression is known to be proliferation dependent in breast cancer (Jarvinen et al, 1996) , it is possible that tumour proliferation had a confounding effect on the predictive value of Topo IHa. By adjusting Topo IIoc for S-phase fraction (by analysing the ratio of Topo IIo to the S-phase fraction), this possibility was also ruled out (Topo IIa/S-phase fraction, statistically not significant).
DISCUSSION
Numerous experimental studies have established that chemosensitivity of cancer cells to Topo II inhibitors depends on the expression level of Topo 11o in the target cells (for review see Froelich-Ammon and Osheroff, 1995; Nitiss and Beck, 1996) . Therefore, the present results showing a lack of correlation between Topo Ixo expression and chemosensitivity clearly contradict the abundant in vitro evidence (Davies et al, 1988; Fry et al, 1991; Gudkov et al, 1993; Asano et al, 1996a,b; Vassetzky et al, 1996; Withoff et al, 1996b) . Our results are, however, similar to those of two small in vivo studies on small numbers of leukaemia and bladder cancer patients (Kaufmann et al, 1994; Davies et al, 1996) . Our immunohistochemical method for the determination of Topo Ixo has been extensively validated (Jarvinen et al, 1996) and shown to reflect closely the exact Topo II enzyme activity of the tissue (Yamazaki et al, 1996) . We also confirmed that measuring Topo 1Ixo expression from the primary tumour (as was done in this study) reflects the expression level in the metastasis, the actual target of chemotherapy. In addition, we concentrated on detecting only the ct-form of Topo II because this isoform is generally considered to be the primary target for Topo IL-inhibiting drugs (Froelich-Ammon and Osheroff, 1995; Nitiss and Beck, 1996) , whereas the role of Topo IlI in relation to chemosensitivity is still obscure (Houlbrook et al, 1996; Sandri et al, 1996; Withoff et al, 1996b) . Thus, after careful validation of the analytical methods, it is likely that Topo IIoc expression (as determined using immunohistochemistry) is not related with response to epirubicin in advanced breast cancer patients. It is therefore possible that the clinical effects of epirubicin may be mediated via other, Topo IIa expression-independent mechanisms, such as generation of free radicals, damage on plasma membranes, lipid peroxidation, ceramide induction, interactions with iron and spontaneous, position-specific DNA lesions (Epstein, 1990; Bose et al, 1995; Kingma and Osheroff, 1997a,b) .
Our study also provided important information of the predictive value of other biomarkers tested. Although it is a generally held view that the response to chemotherapy is dependent on tumour proliferative activity, evidence supporting this concept is controversial (Masters et al, 1987; Hietanen et al, 1995; Clark, 1996) . When DNA flow cytometry has been used to correlate tumour proliferation with response to chemotherapy in advanced breast cancer, both promising and disappointing results have been presented (Masters et al, 1987; Hietanen et al, 1995) . We did not find a significant association between proliferation rate (S-phase fraction) and response to epirubicin. Therefore, it is probably premature to apply tumour proliferation assays into clinical diagnostics to predict the response to chemotherapy.
Another potentially predictive factor in breast cancer is the p53 tumour-suppressor protein because it has been shown that p53 is a key trigger of apoptotic response after DNA damage caused by cytotoxic drugs (Carson and Lois, 1995; Harris, 1996) . Our results on p53 immunohistochemical accumulation, which generally reflects the mutation status of the p53 gene reliably in breast cancer (Soong et al, 1996) , did not support the role of p53 as a significant predictive factor in clinical breast cancer. Neither p53 alone nor p53 after its stratification by Topo IIa expression, proliferation rate or any other factor showed predictive value for chemotherapy response. Thus, the relationship between apoptosis regulators and response to chemotherapy is likely to be more complex. Other genes such as the tumour-suppressor gene p21WAF/CIPi, which recognizes Topo II inhibitor-induced DNA damage (Gartenhaus et al, 1996; Jacks and Weinberg, 1996) , may be also involved in this process.
Among the other biomarkers tested, we identified a strong correlation between hormone receptor status and response to epirubicin. This relationship was especially strong for oestrogen receptor; positive ER expression predicting good response to therapy. The relationship between Topo II inhibitor chemotherapy and hormone receptor content has also been reported previously in two larger studies (Falkson et al, 1991; Muss et al, 1994) . Together, these studies indicate that favourable response to cytotoxic drugs is common in primarily ER-positive tumours, although many of these patients had initially responded and then become resistant to preceding hormonal therapy. The explanation for this phenomenon is unknown. Preliminary in vitro evidence suggests that the absence of oestrogen-mediated signalling pathways (ER negativity) is associated with impaired ability of the cell cycle checkpoints to detect the DNA damage by cytotoxic drugs (Guillot et al, 1996; 1997) .
In addition to the predictive value of hormone receptors, the significant association of c-erbB2 overexpression and resistance to epirubicin is also of particular interest. Previous chemotherapy regimens containing topo II inhibitors have linked c-erbB2 either to sensitivity (Muss et al, 1994) or to resistance (Wright et al, 1992; Ravdin and Chamness, 1995; Bitran et al, 1996) , whereas in vitro studies relate c-erbB2 amplification exclusively to chemoresistance (Pietras et al, 1994; Tsai et al, 1996; Zhang et al, 1996) . The biological mechanism underlying this association is so far unknown. Simultaneous aberrant expression of Topo Ila and c-erbB2 has been suggested as an explanation (Muss et al, 1994; Jarvinen et al, 1996; Murphy et al, 1996) because both genes are located adjacent to each other at chromosome 17q 12. To support this theory, simultaneous amplification of these two genes has been reported in breast cancer cell lines and in clinical breast cancer samples (Keith et al, 1993; Smith et al, 1993; Matsumura et al, 1994; Murphy et al, 1996) . In addition, the Topo Iloa gene may even be physically deleted in conjunction with c-erbB2 amplification (Matsumura et al, 1994 ). Furthermore, high-level Topo Ila expression was associated with c-erB2 overexpression in a large series of breast tumours (Jarvinen et al, 1996) . However, our step-wise logistic regression analysis clearly showed that the adjustment of variability of Topo IIxc expression had no effect on the predictive value of c-erbB2. Therefore, other mechanisms explaining the association of c-erbB2 amplification and poor response are probably more relevant. Although c-erbB2 itself is not a molecular target for cytotoxic drugs, increased tyrosine kinase activity caused by c-erbB2 amplification may be associated with chemoresistance (Pietras et al, 1994; Tsai et al, 1996; Zhang et al, 1996) . Increased tyrosine kinase activity may directly increase repair of DNA damage caused by cytotoxic drugs (Pietras et al, 1994) , thereby making the cells able to avoid apoptosis despite drug treatment.
In conclusion, the present study shows that the response to the Topo II-inhibiting cytotoxic drug, epirubicin, could not be predicted by Topo 11c expression in advanced breast cancer. The response was significantly associated with c-erbB2 overexpression and ER status, indicating that these widely used prognostic factors may have additional value as the predictors of response to firstline anthracycline chemotherapy.
